THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Wednesday, April 22, 2020
The biotechnology firm focuses on discovering and delivering the next generation of targeted cancer therapies
Fremont, CA: Biotechnology firm Tango Therapeutics raised USD 60 million in a Series B round of funding led by Boxer Capital of the Tavistock Group. The round was also participated by new investors Cormorant Asset Management and Casdin Capital. The biotechnology firm focuses on discovering and delivering the next generation of targeted cancer therapies. Additionally, Tango announced leadership appointments of Daniella Beckman, Chief Financial Officer, John C. Ross, Vice President of Human Resources, and Samy Tadros, Vice President of Business Development.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
[vendor_logo_first]"We are very fortunate to have the support of this strong syndicate of cross-over investors as we bring our first targeted therapies based on the genetic concept of synthetic lethality to well-defined patient populations," said Barbara Weber, MD, President and Chief Executive Officer of Tango. "This financing will support our lead program into IND-enabling studies early next year as well multiple other ongoing target and drug discovery efforts."
Daniella Beckman brings more than 20 years of strategic, financial, and operational experience to her role at Tango overseeing finance, investor relations, and business development. Beckman has served as interim Chief Financial Officer for Tango since its inception, and before that, for other early-stage biotechnology companies, including Neon Therapeutics. Previously, she worked as the Chief Financial Officer of Idenix Pharmaceuticals, where she oversaw finance, investor relations, and IT until it was acquired by Merck in 2014.
John C. Ross joins Tango after serving as senior director of human resources for the surgical medical device business at Alcon, formerly a division of Novartis. Ross has helped to facilitate the company's spinoff from Novartis in 2019. Before Alcon, he served in multiple human resources leadership roles in Novartis Oncology and Novartis General Medicines in the U.S. and Europe. "We're thrilled Daniella has agreed to join our team as CFO and to welcome John and Samy into these key leadership roles," added Dr. Weber. "Insights from all three industry leaders will be invaluable as we advance our pipeline of next-generation targeted cancer therapies and bring novel therapies to patients."
See also: Top Biotech Solution Companies
More in News